Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Should You Sell?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) gapped down before the market opened on Wednesday. The stock had previously closed at $11.16, but opened at $10.25. Telix Pharmaceuticals shares last traded at $10.0550, with a volume of 152,870 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TLX shares. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. Finally, Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.50.

Telix Pharmaceuticals Price Performance

The stock has a fifty day moving average price of $11.39 and a 200-day moving average price of $10.79. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TLX. Bank of America Corp DE increased its position in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. XY Capital Ltd purchased a new position in shares of Telix Pharmaceuticals in the 1st quarter valued at $120,000. WoodTrust Financial Corp acquired a new position in shares of Telix Pharmaceuticals during the 3rd quarter valued at $186,000. Private Advisor Group LLC lifted its holdings in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.